The Paranasal Sinus And Nasal Cavity Cancer drugs in development market research report provides comprehensive information on the therapeutics under development for Paranasal Sinus And Nasal Cavity Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Paranasal Sinus And Nasal Cavity Cancer. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Paranasal Sinus And Nasal Cavity Cancer and features dormant and discontinued products.
GlobalData tracks nine drugs in development for Paranasal Sinus And Nasal Cavity Cancer by nine companies/universities/institutes. The top development phase for Paranasal Sinus And Nasal Cavity Cancer is phase ii with nine drugs in that stage. The Paranasal Sinus And Nasal Cavity Cancer pipeline has nine drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Paranasal Sinus And Nasal Cavity Cancer pipeline products market are: AstraZeneca, Compugen and Bristol-Myers Squibb.
The key targets in the Paranasal Sinus And Nasal Cavity Cancer pipeline products market include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1), Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1), and Receptor Type Tyrosine Protein Kinase FLT3 (FMS Like Tyrosine Kinase 3 or FL Cytokine Receptor or Stem Cell Tyrosine Kinase 1 or Fetal Liver Kinase 2 or CD135 or FLT3 or EC 2.7.10.1).
The key mechanisms of action in the Paranasal Sinus And Nasal Cavity Cancer pipeline product include Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) Antagonist with three drugs in Phase II. The Paranasal Sinus And Nasal Cavity Cancer pipeline products include nine routes of administration with the top ROA being Intravenous and two key molecule types in the Paranasal Sinus And Nasal Cavity Cancer pipeline products market including Monoclonal Antibody, and Small Molecule.
Paranasal Sinus And Nasal Cavity Cancer overview
Malignant cells in the tissues of paranasal sinuses and nasal cavity results in paranasal sinus and nasal cavity cancer. It is rare type of cancer categorized into five stages (stage 0- stage 4) and of different types like adenocarcinoma, squamous cell carcinoma, melanoma, lymphoma, sarcoma etc. It can be metastasis in nature. Exposure to chemicals, dust, age, infections like HPV, smoking are the common etiological factors causing this cancer. Headache, runny nose, lump inside the nose, on the face, pain in eyes, vision changes are common signs and symptoms. Physical examination of nose, face, neck followed by radiographic findings, biopsy, laryngoscopy to examine the larynx and nasoscopy are done. Chemotherapy, radiation therapy and surgery to remove the cancer are the treatment options.
For a complete picture of Paranasal Sinus And Nasal Cavity Cancer’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
